{
  "id": 1808696,
  "title": "Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development",
  "url": "https://urgent.news/2026/08/18/psyence-biomed-welcomes-u-s-administrations-latest-action-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T21:26:59.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/psyence-biomed-welcomes-u-s-administrations-latest-action-to-accelerate-ibogaine-development"
  },
  "original_language": "en",
  "account": null,
  "summary": "Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}